The impact of paclitaxel and carboplatin chemotherapy on the autonomous nervous system of patients with ovarian cancer

被引：0
|
作者：
Emmanouil V. Dermitzakis
Vasilios K. Kimiskidis
George Lazaridis
Zoi Alexopoulou
Eleni Timotheadou
Alexandros Papanikolaou
Ourania Romanidou
George Georgiadis
Konstantine T. Kalogeras
Iakovos Tsiptsios
Basil Tarlatzis
George Fountzilas
机构：
[1] “Papageorgiou” Hospital,Laboratory of Clinical Neurophysiology, Department of Neurology
[2] Aristotle University of Thessaloniki,Laboratory of Clinical Neurophysiology
[3] Faculty of Medicine,Department of Medical Oncology, School of Health Sciences, Faculty of Medicine
[4] “Papageorgiou” Hospital,Department of Biostatistics
[5] Aristotle University of Thessaloniki,First Department of Obstetrics and Gynecology, School of Health Sciences, Faculty of Medicine
[6] Health Data Specialists Ltd,Neurological Department
[7] “Papageorgiou” Hospital,Laboratory of Molecular Oncology
[8] Aristotle University of Thessaloniki,undefined
[9] “Hippocration” General Hospital,undefined
[10] Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki,undefined
[11] Translational Research Section,undefined
[12] Hellenic Cooperative Oncology Group,undefined
[13] Data Office,undefined
来源：
BMC Neurology | / 16卷
关键词：
30/15 ratio; Autonomous nervous system; Orthostatic hypotension; Paclitaxel; Sympathetic skin response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Is docetaxel-carboplatin an alternative to paclitaxel-carboplatin in ovarian cancer?
    Vasey, PA
    Coleman, R
    Eggleton, SPH
    Graham, J
    Fleming, D
    Paul, J
    Reed, NS
    Kaye, S
    BRITISH JOURNAL OF CANCER, 1999, 80 : 14 - 14
  • [42] Comparison of the Short term Efficacy and Serum Markers between Lobaplatin/Paclitaxel and Carboplatin/Paclitaxel-based Adjuvant Chemotherapy in Patients with Ovarian Cancer
    Li, Zhihui
    Chen, Ying
    Zhang, Shihong
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 82 : 23 - 29
  • [43] Sequentially insert of carboplatin followed by Paclitaxel in the first-line therapy for ovarian cancer carboplatin followed by Paclitaxel in the therapy for ovarian cancer
    Sehouli, J.
    Mustea, A.
    Pfisterer, J.
    Camara, O.
    Lichtenegger, W.
    Oskay-Oezcelik, G.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2008, 68 : S70 - S70
  • [44] Relationship between thrombocytopenia and survival of patients with epithelial ovarian cancer (EOC) who received paclitaxel and carboplatin chemotherapy.
    Nagao, S
    Fujiwara, K
    Imafuku, N
    Kozuka, Y
    Kagawa, R
    Oda, T
    Maehata, K
    Ishikawa, H
    Koike, H
    Kohno, I
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 466S - 466S
  • [45] Risk factors for recurrence of optimally staged/debulked ovarian or tubal cancer patients with adjuvant paclitaxel/carboplatin combination chemotherapy
    Kojimahara, T.
    Nakahara, K.
    Osakabe, M.
    Saitoh-Sekiguchi, M.
    Hayasaka, T.
    Motoyama, T.
    Kurachi, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [46] Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness
    Miranda, Vanessa da Costa
    de Souza Fede, Angelo Bezerra
    dos Anjos, Carlos Henrique
    da Silva, Juliana Ribeiro
    Sanchez, Fernando Barbosa
    da Silva Bessa, Lyvia Rodrigues
    Carvalho, Jesus de Paula
    Abdo Filho, Elias
    de Freitas, Daniela
    Estevez Diz, Maria del Pilar
    GYNECOLOGIC ONCOLOGY, 2014, 132 (02) : 287 - 291
  • [47] Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer
    duBois, A
    Luck, HJ
    Meier, W
    Mobus, V
    Costa, S
    Richter, B
    Bauknecht, T
    Warm, M
    Schroeder, W
    Olbricht, S
    Nitz, U
    Jackisch, C
    SEMINARS IN ONCOLOGY, 1997, 24 (04) : 28 - 33
  • [48] Surgical cytoreduction and dose intensity of adjuvant paclitaxel and carboplatin chemotherapy in advanced epithelial ovarian cancer
    Shafer, A.
    Rubatt, J. M.
    Ayeni, T.
    Deal, A. M.
    Secord, A. A.
    Soper, J. T.
    Havrilesky, L. J.
    Van Le, L.
    Gehring, P. A.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S55 - S56
  • [49] Pharmacokinetics of combination chemotherapy with paclitaxel and carboplatin in a patient with advanced epithelial ovarian cancer undergoing hemodialysis
    Kodama, Junichi
    Sasaki, Aiko
    Masahiro, Satoko
    Seki, Noriko
    Kusumoto, Tomoyuki
    Nakamura, Keiichiro
    Hongo, Atsushi
    Hiramatsu, Yuji
    ONCOLOGY LETTERS, 2010, 1 (03) : 511 - 513
  • [50] First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer - a new standard of care?
    du Bois, A
    Neijt, JP
    Thigpen, JT
    ANNALS OF ONCOLOGY, 1999, 10 : 35 - 41
12345